Regeneron Pharmaceuticals continues to be under scrutiny as it experiences share fluctuations and anticipation around key decisions. Several wealth management companies, such as Marietta, Sowell Financial Services, Clarius Group, and Janney Montgomery Scott LLC,
increased their positions in the pharmaceutical giant, while others like Warther and Fifth Third Bancorp
decreased their stakes. Among major events, 23andMe's race with an
offer from Regeneron resulting in Regeneron's
withdrawal. The company also completed
key resolutions at its annual meeting, with FDA
approval for two new uses for their
drugs, including its collaboration with
Sanofi. It reported a 27% reduction in the exacerbation of Chronic Obstructive Pulmonary Disease (
COPD) in a Phase 3 trial, but also faced
failure in another test related to smoker's lung treatment. It also secured an $80 million deal. Despite these activities, the stock has been downgraded recently by Citigroup and Wells Fargo due to
lowered expectations. Yet, prestigious investors such as Mario Gabelli and Wall Street
analysts note Regeneron among their top large-cap
stock picks.
Regeneron Pharmaceuticals REGN News Analytics from Tue, 25 Feb 2025 08:00:00 GMT to Sat, 21 Jun 2025 10:53:28 GMT -
Rating -2
- Innovation 7
- Information 5
- Rumor -5
